<DOC>
	<DOCNO>NCT00838877</DOCNO>
	<brief_summary>The study carry order investigate [ 18F ] AZD4694 , compare [ 11C ] AZD2184 , suitable PET ligand vivo image Aβ amyloid deposition human brain . In study two PET ligand examine healthy volunteer patient Alzheimer 's Disease . A whole body dosimetry scan perform 6 healthy volunteer obtain human data estimate safe dose .</brief_summary>
	<brief_title>Positron Emission Tomography ( PET ) Study With 18FAZD4694 11CAZD2184 , Candidate PET Ligands Aβ Amyloid</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Alzheimer 's Disease patient 5085 year , mild moderate AD : MMSE ≥16 ≤ 26 , clinical progression AD 12 month . Healthy volunteer : 5075 year BMI 18 30 m2/kg Clinically normal physical finding include supine blood pressure pulse rate . Alzheimer 's Disease patient Clinically significant illness 2 week prior administration PET ligand Significant cerebrovascular disease depression , central nervous system infarct infection lesion Administration investigational product within 3 month prior study and/or PET measurement scientific purpose within last 12 month . Healthy volunteer clinically significant illness within 2 week administration PET ligand , history psychiatric somatic disease/condition may interfere , first degree relative dementia . Obvious deterioration memory function .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>PET</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Positron Emission Tomography</keyword>
</DOC>